Oct 21, 2025 02:00AM
Oct 21, 2025 02:00AM
Aug 18, 2025 09:11AM
Aug 18, 2025 09:10AM
Jul 18, 2025 11:31AM
Jul 18, 2025 11:30AM
Jun 20, 2025 08:01AM SpringWorks Therapeutics (SWTX) Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
Jun 20, 2025 08:00AM
May 23, 2025 08:00AM
May 23, 2025 08:00AM
Feb 19, 2025 08:00AM
Feb 11, 2025 08:20PM
Feb 11, 2025 05:32PM
Feb 11, 2025 05:27PM SpringWorks Therapeutics Announces FDA Approval of GOMEKLI™ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN 
Nov 11, 2024 07:00AM
Nov 11, 2024 06:30AM
Nov 7, 2024 06:30AM
Nov 7, 2024 06:30AM
Aug 28, 2024 06:31AM
Aug 28, 2024 06:30AM
Jul 1, 2024 06:31AM SpringWorks Therapeutics Inc. (SWTX) Completes Submission of NDA for Mirdametinib
Jul 1, 2024 06:30AM
May 23, 2024 05:13PM
Apr 24, 2024 01:31PM
Mar 4, 2024 06:31AM
Mar 4, 2024 06:30AM
Feb 29, 2024 08:32AM
Feb 29, 2024 08:30AM SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
Nov 27, 2023 06:05PM
Nov 27, 2023 06:04PM
Nov 16, 2023 06:31AM
Nov 16, 2023 06:30AM
May 25, 2023 05:06PM
May 11, 2023 12:17PM
May 11, 2023 12:14PM SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
Feb 27, 2023 06:30AM
Feb 27, 2023 06:30AM
Feb 27, 2023 06:30AM
Dec 27, 2022 06:32AM
Dec 27, 2022 06:30AM
Dec 27, 2022 06:30AM
Nov 29, 2021 06:30AM SpringWorks Therapeutics Announces Full Enrollment of Phase 2b ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with NF1-Associated Plexiform Neurofibromas
Nov 29, 2021 06:30AM
Sep 12, 2019 07:00AM

64,524 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All